companies innovating obesity treatment glp-1 drugs 2025 to reshape pharma landscape GLP-1 Agonists Weight Loss Drugs

2026: Acceleration and Market Transformation The coming year promises rapid evolution across innovation, policy, and market access

In collaboration with Novo Nordisk, Hims & Hers soon will offer access to the only FDA-approved GLP-1 weight loss pill, alongside injectable Wegovy in all dosages

Wondering about GLP-1 dosing approaches

Yes, eligible beneficiaries can get Wegovy or Zepbound for $50/month through the temporary Bridge Program.

Learn how different GLP-1 medications work, how they differ for weight loss vs diabetes and why dual agonists like tirzepatide stand out.

For local players, this reinforces the role of licensing and distribution alliances as a practical path to compete in the global #obesity market ahead of full-scale innovation or manufacturing build-out